Opinion|Videos|September 3, 2024
Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation
Author(s)Larysa Sanchez, MD, Samantha Shenoy, NP, MSN
Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some of the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer therapies?
- How do you prepare patients who are going to receive GPRC5D therapy? What are you telling them?
Advertisement
Related to this article
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
5